Aripiprazole-related tardive dyskinesia

CNS Spectrums

Volumn 11, Issue 6, 2006, Pages 435-439

  Maytal, Guy ^a,b   Ostacher, Michael ^a,b   Stern, Theodore A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; HEAVY METAL; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PHYSOSTIGMINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ADULT; AGORAPHOBIA; ARTICLE; CASE REPORT; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; INVOLUNTARY MOVEMENT; MAJOR DEPRESSION; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 33745309324     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014632     Document Type: Article

References (28)

1. Matza LS, Baker TM, Revicki DA. Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. CNS Drugs. 2005;19:499-515.
2. Hargreaves WA, Gibson JP. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs. 2005;19:393-410.
3. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002;63:95-103.
4. Kane J. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl 9):16-20.
5. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191-208.
6. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry. 2005;50:188.
7. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry. 2003;48:771-772.
8. Fogel BS, Schiffer RB, Rao SM, eds. Neuropsychiatry. Baltimore, Md: Williams & Wilkins; 1996.
9. Hyman SE, Arana GW, Rosenbaum JF, eds. Handbook of Psychiatric Drug Therapy. 3rd ed. Boston, Mass Little Brown and Company: 1995:35-37.
10. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
11. Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, Penn: Lippincott Williams & Wilkins; 2000.
12. Aparasu RR, Bhatara V, Gupta S. U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry. 2005;17:147-152.
13. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6:79-83.
14. Click ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35:187-191.
15. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
16. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703-714.
17. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry. 2006;18:57-62.
18. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;10:[Epub ahead of print].
19. Carpenter WT Jr, Bartko JJ, Carpenter CL, Strauss JS. Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry. 1976;33:508-516.
20. Alexopoulos GS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis. 1979;167:125-127.
21. Myslobodsky MS, Tomer R, Holden T, Kempler S, Sigal M. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis. 1985;173:156-160.
22. Arango C, Adami H, Sherr JD, Thaker GK, Carpenter WT Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry. 1999;156:1097-1099.
23. Blanchet PJ, Rompre PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005;18:10-19.
24. Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:626-628.
25. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23-45.
26. Bristol-Meyers Squibb product information for Ability (aripiprazole). Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_ PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI. Accessed on April 4, 2006.
27. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry. 2005;50:188.
28. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry. 2005;7:36.